Purchase Order 75F40118P20140
Award Date 7/17/18
Potential Completion Date 7/18/19
Potential Value $151K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
St. Louis, MO 63105, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Food and Drug Administration (FDA) awarded a $65,451.84 firm fixed-price purchase order to Certara USA Inc. (doing business as Tripos (De)) for Phoenix Quantum licenses and support services. The contract was awarded on July 11, 2019, with an ultimate completion date of July 11, 2024, and was performed in Princeton, New Jersey. This contract reflects the FDA's ongoing reliance on Certara's pharmacokinetic and pharmacodynamic modeling software to support regulatory review activities and drug...
- The Department of Health and Human Services, Food and Drug Administration awarded a fixed-price purchase order contract to Certara USA Inc., doing business as Tripos (De), for an annual Phoenix Quantum software subscription. The contract, with a potential value of $216,547.78, provides the FDA's Office of Clinical Pharmacology with the necessary modeling and simulation tools to analyze and verify sponsor submissions, including Investigational New Drug, New Drug, Biologics Licensing, and...
- This is a $91,396 firm fixed-price purchase order issued by the Food and Drug Administration (FDA) to Certara USA Inc., doing business as Tripos (De), for the ratification of Phoenix Quantum licenses in fiscal year 2017. Certara is a technology-enabled drug development and drug safety consultancy that specializes in biosimulation and has received multiple federal contracts from the Department of Health and Human Services, including the FDA, National Institutes of Health, and Centers for...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Pharsight Corporation, a subsidiary of Certara USA Inc. The contract, valued at $153,470.00, is for the provision of the "PHOENIX QUANTUM SOFTWARE BUNDLE" and is a total small business set-aside. The contract has a completion date of July 21, 2017. Certara USA Inc. is a leading global technology-enabled drug development and drug safety consultancy, specializing in biosimulation...
- This is a $169,504.71 firm-fixed price purchase order awarded by the U.S. Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Certara USA Inc., doing business as Tripos (DE), a technology-enabled drug development and drug safety consultancy. The contract provides annual named user server licenses for Certara's Phoenix WinNonlin, Phoenix Connect, Phoenix NLME software, as well as an unlimited server license for distributed computing. This supports the FDA's...
- This is a $11,682 firm-fixed-price purchase order contract awarded by the National Institute on Drug Abuse, a civilian agency within the U.S. Department of Health and Human Services, to Certara USA Inc. The contract is for the licensing and subscription of Certara's proprietary biosimulation and data exploration software tools, including Phoenix WinNonlin, Certara Phoenix, CHEMOFFICE, and SEND EXPLORER. These software products enable federal scientists and reviewers at the National Institutes of...
- This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Certara USA Inc., a leading provider of biosimulation software and consulting services. The contract, valued at $16,441.10, is for the procurement of software licenses for Certara's proprietary modeling and simulation tools, including Phoenix WinNonlin, Certara Phoenix, CHEMOFFICE, and SEND EXPLORER. These software products enable federal scientists and reviewers to conduct...
- This is a $845,852.26 firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Certara USA Inc. for the licensing of the company's CDER CERTARA PHOENIX software products. The award is not associated with a set-aside program and is intended to provide the FDA's Office of Clinical Pharmacology with necessary software tools, including Phoenix WinNonlin, NLME, IVIVC, Connect, and Trial Simulator, to support the review of Investigational New Drug (IND), New Drug...
- The U.S. Food and Drug Administration (FDA) awarded a firm fixed price purchase order to Certara UK Limited, doing business as Certara, a for-profit limited liability company, for SIMCYP software licenses and maintenance support. The $114,316.00 contract will allow the FDA's Office of Clinical Pharmacology Drug Reviewers to complete their review of investigational new drugs. Certara has previously provided this physiologically-based pharmacokinetic modeling software to the FDA and...
- The Department of Health and Human Services' National Institutes of Health has awarded a firm fixed-price purchase order to Certara USA Inc., a leading global drug development and drug safety consultancy, for the provision of Phoenix WinNonlin software licenses. The $12,266.00 contract will enable federal scientists and reviewers to conduct clinical pharmacology, pharmacometric, and regulatory review analyses on data submitted by industry sponsors. Certara has received numerous prime contracts...